Cargando…
Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours
BACKGROUND: Radionuclide therapy can be individualized by performing dosimetry. To determine absorbed organ doses in (177)Lu-DOTATATE therapy, three methods based on activity concentrations are currently in use: the small volume of interest (sVOI) method, and two methods based on large VOIs either o...
Autores principales: | Sandström, Mattias, Ilan, Ezgi, Karlberg, Anna, Johansson, Silvia, Freedman, Nanette, Garske-Román, Ulrike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883125/ https://www.ncbi.nlm.nih.gov/pubmed/26501825 http://dx.doi.org/10.1186/s40658-015-0127-y |
Ejemplares similares
-
Peptide Receptor Radionuclide Therapy (PRRT) with (177)Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
por: Jahn, Ulrika, et al.
Publicado: (2021) -
Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
por: Sandström, Mattias, et al.
Publicado: (2020) -
Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017) -
Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019) -
The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with (177)Lu DOTATATE (LuTate)
por: Alipour, R., et al.
Publicado: (2023)